Moreover, the results highlighted the idea that MVO could regulate the expression levels of targets, especially for TNF, CHRM1, ACE, IL10, PTGS2, REN, and F2, as well as neuroactive ligand–receptor interaction, the calcium signaling pathway, and PI3K-Akt signaling pathway to treat hypertension. The gene discussed is CHRM1; the disease is hypertensive disorder.